Don’t Apologize for Choosing Your Health: Weight-Loss Injections and Unwarranted Shame
In this article
Breaking Down “Walls of Shame” as Access to GLP-1 Drugs Expands: Prescribing Is Only Half the Job
As GLP-1 receptor agonists, known as weight-loss injections (semaglutide / Ozempic, tirzepatide / Mounjaro , etc.), become increasingly common in diabetes and weight management, many doctors are discovering an important truth: Prescribing the drug is only half the battle. The other half lies in communication with the patient. Even as access grows, stigma surrounding weight and obesity continues to shape how doctors and patients discuss these drugs and how comfortable patients feel about starting treatment.
Key message: Weight-management experts emphasize that, when explaining GLP-1 treatments to people with obesity or overweight, small, deliberate changes in tone, framing and the follow-up approach can create, in patient cooperation, trust and treatment adherence, measurable and meaningful differences . Obesity is not a matter of willpower; it is a complex disease with biological, genetic and environmental components , and our clinical language must reflect this reality.
1) Why Does Stigma Persist?
The American Medical Association (AMA) officially classified obesity as a disease in 2013. Yet the narrative in many consulting rooms still revolves around personal responsibility and appearance . Experts emphasize that obesity is a chronic, relapsing disease involving biological, genetic and environmental factors.
Physician Bias: The “Easy Way Out” Misconception
Many physicians assume that a patient requesting GLP-1 treatment is seeking an “easy way out.” Yet the vast majority of people struggling with weight already enter the consulting room with feelings of guilt and shame . Scientific data clearly show that, beyond a certain weight threshold, obesity is no longer simply behavioral; it becomes an epigenetic biological process shaped by genetic predispositions and environmental factors .
The Real-World Impact: Patients Avoid Appointments
Obesity published a survey in September 2023 with striking findings:
Result: Weight bias in healthcare is directly linked to delayed preventive care, poorer metabolic control and reduced patient–physician trust. Patients encounter many “subconscious whispers,” from the size of examination tables to an immediate focus on weight when they seek help for an unrelated complaint (e.g., knee pain).
Changing the Conversation: Tips for Doctors
Experts note that the “language of care” around obesity involves all staff, not only doctors. Here are some strategies for reframing the conversation:
- Define the Disease: Frame obesity as a chronic metabolic disease requiring treatment, like diabetes or hypertension. Focus on physiology and health rather than appearance.
- Choose Terminology Carefully: Use person-centered language such as “a person with obesity,” rather than labeling terms such as “obese” or “fat.”
- Emphasize the Long-Term Commitment: Clearly explain that GLP-1s are not a “quick fix” for a few months, that weight returns after discontinuation and that this is long-term treatment.
- Show Empathy and Validation: Normalize the patient’s struggle and reduce blame with statements such as “Your experience is shared by many people I see.”
DROZDOGAN Academy Commentary
This article points to one of modern medicine’s greatest contradictions: we have revolutionary treatments —GLP-1s—yet the greatest barrier to patients accessing them remains our old prejudices and stigma. Our responsibility as physicians extends beyond writing prescriptions; it includes breaking down the barriers of shame, guilt and judgment that prevent patients from accessing treatment. When we stop viewing obesity as weak willpower and start treating it as a complex, chronic metabolic disease , real progress in both clinical outcomes and the patient–physician relationship will become possible.
Looking Ahead
As GLP-1 treatment costs fall and access expands, we expect stigma around these drugs to decrease naturally . If a GLP-1 pill could replace several medicines you take for blood pressure, cholesterol and kidney disease, we would discuss it as routinely and neutrally as we discuss statins today . True equity begins with a medical approach in which prescribing decisions are not based on the patient’s appearance but on their clinical need .
Source: Breaking Through the Stigma as Access Expands to GLP-1s. Medscape. December 19, 2025.
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.